EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the injections. Nearly 400 users have been hospitalised with serious, ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...
The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...
1d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.
The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback